+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Multiple Myeloma Disease Coverage Forecast and Market Analysis to 2024

  • ID: 3797420
  • Report
  • 746 pages
  • Datamonitor Healthcare
1 of 2
Disease Overview
Multiple myeloma is characterized by the infiltration of malignant, antibody-producing plasma cells in the bone marrow. Almost all cases occur in individuals aged over 40 years, and age at diagnosis has an impact on patient outcome, especially in terms of the treatment options available. Most patients will receive at least three lines of treatment, and eligible patients will receive stem cell transplantation.

Market Snapshot
  • Generic erosion of Revlimid will be a major growth resistor in the multiple myeloma market.
  • Alongside SCT, several triplet combination regimens are used as standard treatment for patients across all lines of therapy.
  • The incident population is forecast to undergo a substantial 39%increase from 58,200 cases in 2017 to 81,050 in 2037.
  • A number of leading multiple myeloma drugs will soon face generic competition.
  • Pipeline candidates will use novel mechanisms of action as distinguishing factors in an increasingly crowded market.
  • High-cost combination regimens pose a significant challenge for payers.
Note: Product cover images may vary from those shown
2 of 2
FORECAST: MULTIPLE MYELOMA (Published on 09 August 2018)
  • Overview
  • Recent Forecast Updates
  • Market Dynamics
  • Forecast And Future Trends
  • Market Definition And Methodology
  • Primary Research Methodology
  • Bibliography
  • Product Profile: Darzalex
  • Product Profile: Empliciti
  • Product Profile: Farydak
  • Product Profile: Kyprolis
  • Product Profile: Ninlaro
  • Product Profile: Pomalyst
  • Product Profile: Revlimid
  • Product Profile: Thalomid
  • Product Profile: Treanda
  • Product Profile: Velcade
  • Product Profile (Late Stage): Venclexta
  • Product Profile (Late Stage): Ygalo
  • Product Profile (Late Stage): Bb2121
  • Product Profile (Late Stage): Isatuximab
  • Product Profile (Late Stage): Selinexor
TREATMENT: MULTIPLE MYELOMA (Published on 26 October 2018)
  • Overview
  • Primary Research Methodology
  • Disease Definition And Diagnosis
  • Patient Segmentation
  • Current Treatment Options
  • Prescribing Trends
EPIDEMIOLOGY: MULTIPLE MYELOMA (Published on 08 August 2018)

OVERVIEW
  • Disease Background
  • Methodology
  • Forecast
  • Bibliography
  • Appendix: Additional Sources
MARKETED DRUGS: MULTIPLE MYELOMA (Published on 09 August 2018)
  • Overview
  • Product Overview
  • Product Profile: Darzalex
  • Product Profile: Empliciti
  • Product Profile: Farydak
  • Product Profile: Kyprolis
  • Product Profile: Ninlaro
  • Product Profile: Pomalyst
  • Product Profile: Revlimid
  • Product Profile: Thalomid
  • Product Profile: Treanda
  • Product Profile: Velcade
MULTIPLE MYELOMA PRICING, REIMBURSEMENT, AND ACCESS (Published on 05 March 2019)
  • Overview
  • Regulatory Labels
  • Global Access Levers
  • Evidence And Value
  • Access To Recently Approved And Pipeline Drugs
  • Pricing
  • Us
  • Canada
  • Japan
  • France
  • Germany
  • Italy
  • Spain
  • Uk
  • Methodology
PIPELINE: MULTIPLE MYELOMA (Published on 09 August 2018)
  • Overview
  • Clinical Pipeline Overview
  • Additional Pharma Intelligence Pipeline Resources
  • Product Profile (Late Stage): Venclexta
  • Product Profile (Late Stage): Ygalo
  • Product Profile (Late Stage): Bb2121
  • Product Profile (Late Stage): Isatuximab
  • Product Profile (Late Stage): Selinexor
LIST OF FIGURES
Figure 1: Multiple myeloma – current and future market dynamics analysis
Figure 2: The author's assessment summary of key marketed and pipeline drugs for multiple myeloma
Figure 3: Multiple myeloma sales across the US, Japan, and five major EU markets, by country, 2017–26
Figure 4: Sales of major multiple myeloma drugs in the US, Japan, and five major EU markets, by product, 2017−26
Figure 5: Combined sales of Darzalex, Empliciti, Ninlaro, and Kyprolis in the US, Japan, and five major EU markets, by drug, 2017−26
Figure 6: Sales of Darzalex and Empliciti in the US, Japan, and five major EU markets, by drug, 2017−26
Figure 7: Sales of Pomalyst and Kyprolis in the US, Japan, and five major EU markets, by drug, 2017−26
Figure 8: Sales of pipeline drugs in the US, Japan, and five major EU markets, by drug, 2017−26
Figure 9: Multiple myeloma sales across the US, Japan, and five major EU markets, by class, 2017–26
Figure 10: Patient-based forecast methodology for multiple myeloma
Figure 11: Price sources and calculations, by country
Figure 12: Darzalex for multiple myeloma – SWOT analysis
Figure 13: The author's drug assessment summary of Darzalex for multiple myeloma
Figure 14: The author's drug assessment summary of Darzalex for multiple myeloma
Figure 15: Darzalex sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 16: Empliciti for multiple myeloma – SWOT analysis
Figure 17: The author's drug assessment summary of Empliciti for multiple myeloma
Figure 18: The author's drug assessment summary of Empliciti for multiple myeloma
Figure 19: Empliciti sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 20: Farydak for multiple myeloma – SWOT analysis
Figure 21: The author's drug assessment summary of Farydak for multiple myeloma
Figure 22: The author's drug assessment summary of Farydak for multiple myeloma
Figure 23: Farydak sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 24: Kyprolis for multiple myeloma – SWOT analysis
Figure 25: The author's drug assessment summary of Kyprolis for multiple myeloma
Figure 26: The author's drug assessment summary of Kyprolis for multiple myeloma
Figure 27: Kyprolis sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 28: Ninlaro for multiple myeloma – SWOT analysis
Figure 29: The author's drug assessment summary of Ninlaro for multiple myeloma
Figure 30: The author's drug assessment summary of Ninlaro for multiple myeloma
Figure 31: Ninlaro sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 32: Pomalyst for multiple myeloma – SWOT analysis
Figure 33: The author's drug assessment summary of Pomalyst for multiple myeloma
Figure 34: The author's drug assessment summary of Pomalyst for multiple myeloma
Figure 35: Pomalyst sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 36: Revlimid for multiple myeloma – SWOT analysis
Figure 37: The author's drug assessment summary of Revlimid for multiple myeloma
Figure 38: The author's drug assessment summary of Revlimid for multiple myeloma
Figure 39: Revlimid sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 40: Thalomid for multiple myeloma – SWOT analysis
Figure 41: The author's drug assessment summary of Thalomid for multiple myeloma
Figure 42: The author's drug assessment summary of Thalomid for multiple myeloma
Figure 43: Thalomid sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 44: Treanda/Bendeka for multiple myeloma – SWOT analysis
Figure 45: The author's drug assessment summary of Treanda/Bendeka for multiple myeloma
Figure 46: The author's drug assessment summary of Treanda/Bendeka for multiple myeloma
Figure 47: Treanda/Bendeka sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 48: Velcade for multiple myeloma – SWOT analysis
Figure 49: The author's drug assessment summary of Velcade for multiple myeloma
Figure 50: The author's drug assessment summary of Velcade for multiple myeloma
Figure 51: Velcade sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 52: Venclexta for multiple myeloma – SWOT analysis
Figure 53: The author's drug assessment summary for Venclexta in multiple myeloma
Figure 54: The author's drug assessment summary for Venclexta for multiple myeloma
Figure 55: Venclexta sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 56: Ygalo for multiple myeloma – SWOT analysis
Figure 57: The author's drug assessment summary for Ygalo in multiple myeloma
Figure 58: The author's drug assessment summary for Ygalo for multiple myeloma
Figure 59: Ygalo sales for multiple myeloma across the US and five major EU markets, by country, 2017–26
Figure 60: bb2121 for multiple myeloma – SWOT analysis
Figure 61: The author's drug assessment summary for bb2121 in multiple myeloma
Figure 62: The author's drug assessment summary for bb2121 in multiple myeloma
Figure 63: bb2121 sales for multiple myeloma across the US and five major EU markets, by country, 2017–26
Figure 64: Isatuximab for multiple myeloma – SWOT analysis
Figure 65: The author's drug assessment summary for isatuximab in multiple myeloma
Figure 66: The author's drug assessment summary for isatuximab in multiple myeloma
Figure 67: Isatuximab sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 68: Selinexor for multiple myeloma – SWOT analysis
Figure 69: The author's drug assessment summary for selinexor in multiple myeloma
Figure 70: The author's drug assessment summary for selinexor in multiple myeloma
Figure 71: Selinexor sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 72: Multiple myeloma patient segmentation, by active and smoldering disease
Figure 73: Active multiple myeloma staging according to the R-ISS system, by country
Figure 74: Primary treatment options for smoldering multiple myeloma patients, by country
Figure 75: Top three pharmacological regimens used for smoldering multiple myeloma treatment, by country
Figure 76: Active SCT-eligible multiple myeloma patients receiving each line of therapy, by country
Figure 77: Active SCT-ineligible multiple myeloma patients receiving each line of therapy, by country
Figure 78: Top three regimens used for induction treatment of SCT-eligible multiple myeloma patients, by country
Figure 79: Consolidation therapy type for SCT-eligible multiple myeloma patients, by country
Figure 80: Top three pharmacological consolidation regimens used for SCT-eligible multiple myeloma patients, by country
Figure 81: Maintenance therapy type for SCT-eligible multiple myeloma patients, by country
Figure 82: Top three regimens used for pharmacological maintenance therapy alone in SCT-eligible patients, by country
Figure 83: Top three regimens used for pharmacological maintenance therapy after tandem autologous SCT, by country
Figure 84: Second-line therapy type for SCT-eligible multiple myeloma patients, by country
Figure 85: Top three pharmacological regimens used at second line for SCT-eligible multiple myeloma patients, by country
Figure 86: Third-line therapy type for SCT-eligible multiple myeloma patients, by country
Figure 87: Top three pharmacological regimens used at third line for SCT-eligible multiple myeloma patients, by country
Figure 88: Top three regimens used in fourth-line therapy for active SCT-eligible multiple myeloma patients, by country
Figure 89: Top three regimens used in fifth-line therapy and beyond for active SCT-eligible multiple myeloma patients, by country
Figure 90: Top three regimens used for induction treatment of multiple myeloma patients not eligible for SCT, by country
Figure 91: Top three regimens used for consolidation treatment of multiple myeloma patients not eligible for SCT, by country
Figure 92: Top three regimens used for maintenance treatment of multiple myeloma patients not eligible for SCT, by country
Figure 93: Top three pharmacological regimens used at second line for multiple myeloma patients not eligible for SCT, by country
Figure 94: Top three pharmacological regimens used at third line for multiple myeloma patients not eligible for SCT, by country
Figure 95: Top three regimens used at fourth line for multiple myeloma patients not eligible for SCT, by country
Figure 96: Top three regimens used at fifth line and beyond for multiple myeloma patients not eligible for SCT, by country
Figure 97: Trends in incident cases of multiple myeloma in the US, Japan, and five major EU markets, by country, 2017–37
Figure 98: Darzalex for multiple myeloma – SWOT analysis
Figure 99: The author's drug assessment summary of Darzalex for multiple myeloma
Figure 100: The author's drug assessment summary of Darzalex for multiple myeloma
Figure 101: Darzalex sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 102: Empliciti for multiple myeloma – SWOT analysis
Figure 103: The author's drug assessment summary of Empliciti for multiple myeloma
Figure 104: The author's drug assessment summary of Empliciti for multiple myeloma
Figure 105: Empliciti sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 106: Farydak for multiple myeloma – SWOT analysis
Figure 107: The author's drug assessment summary of Farydak for multiple myeloma
Figure 108: The author's drug assessment summary of Farydak for multiple myeloma
Figure 109: Farydak sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 110: Kyprolis for multiple myeloma – SWOT analysis
Figure 111: The author's drug assessment summary of Kyprolis for multiple myeloma
Figure 112: The author's drug assessment summary of Kyprolis for multiple myeloma
Figure 113: Kyprolis sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 114: Ninlaro for multiple myeloma – SWOT analysis
Figure 115: The author's drug assessment summary of Ninlaro for multiple myeloma
Figure 116: The author's drug assessment summary of Ninlaro for multiple myeloma
Figure 117: Ninlaro sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 118: Pomalyst for multiple myeloma – SWOT analysis
Figure 119: The author's drug assessment summary of Pomalyst for multiple myeloma
Figure 120: The author's drug assessment summary of Pomalyst for multiple myeloma
Figure 121: Pomalyst sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 122: Revlimid for multiple myeloma – SWOT analysis
Figure 123: The author's drug assessment summary of Revlimid for multiple myeloma
Figure 124: The author's drug assessment summary of Revlimid for multiple myeloma
Figure 125: Revlimid sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 126: Thalomid for multiple myeloma – SWOT analysis
Figure 127: The author's drug assessment summary of Thalomid for multiple myeloma
Figure 128: The author's drug assessment summary of Thalomid for multiple myeloma
Figure 129: Thalomid sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 130: Treanda/Bendeka for multiple myeloma – SWOT analysis
Figure 131: The author's drug assessment summary of Treanda/Bendeka for multiple myeloma
Figure 132: The author's drug assessment summary of Treanda/Bendeka for multiple myeloma
Figure 133: Treanda/Bendeka sales for multiple myeloma across the US, Japan, and five major EU markets, by country,2017–26
Figure 134: Velcade for multiple myeloma – SWOT analysis
Figure 135: The author's drug assessment summary of Velcade for multiple myeloma
Figure 136: The author's drug assessment summary of Velcade for multiple myeloma
Figure 137: Velcade sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 138: Price sources and calculations, by country
Figure 139: Venclexta for multiple myeloma – SWOT analysis
Figure 140: The author's drug assessment summary for Venclexta in multiple myeloma
Figure 141: The author's drug assessment summary for Venclexta for multiple myeloma
Figure 142: Venclexta sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 143: Ygalo for multiple myeloma – SWOT analysis
Figure 144: The author's drug assessment summary for Ygalo in multiple myeloma
Figure 145: The author's drug assessment summary for Ygalo for multiple myeloma
Figure 146: Ygalo sales for multiple myeloma across the US and five major EU markets, by country, 2017–26
Figure 147: bb2121 for multiple myeloma – SWOT analysis
Figure 148: The author's drug assessment summary for bb2121 in multiple myeloma
Figure 149: The author's drug assessment summary for bb2121 in multiple myeloma
Figure 150: bb2121 sales for multiple myeloma across the US and five major EU markets, by country, 2017–26
Figure 151: Isatuximab for multiple myeloma – SWOT analysis
Figure 152: The author's drug assessment summary for isatuximab in multiple myeloma
Figure 153: The author's drug assessment summary for isatuximab in multiple myeloma
Figure 154: Isatuximab sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 155: Selinexor for multiple myeloma – SWOT analysis
Figure 156: The author's drug assessment summary for selinexor in multiple myeloma
Figure 157: The author's drug assessment summary for selinexor in multiple myeloma
Figure 158: Selinexor sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26

LIST OF TABLES
Table 1: Multiple myeloma sales across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 2: Combined sales of Darzalex, Empliciti, Ninlaro, and Kyprolis in the US, Japan, and five major EU markets, by drug ($m), 2017−26
Table 3: Sales of Pomalyst and Kyprolis in the US, Japan, and five major EU markets, by drug ($m), 2017−26
Table 4: Sales of pipeline drugs in the US, Japan, and five major EU markets, by drug ($m), 2019−26
Table 5: Multiple myeloma sales across the US, Japan, and five major EU markets, by class and brand ($m), 2017–26
Table 6: Exchange rates used for calculating prices
Table 7: Medical oncologists and hematologists surveyed for the multiple myeloma primary research study, 2017
Table 8: Darzalex drug profile
Table 9: Darzalex pivotal trial data in multiple myeloma
Table 10: Darzalex early-phase trial data in multiple myeloma
Table 11: Darzalex Phase III trials in multiple myeloma
Table 12: Darzalex sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 13: Patients treated with Darzalex across the US, Japan, and five major EU markets, by country, 2017–26
Table 14: Empliciti drug profile
Table 15: Empliciti pivotal trial data in multiple myeloma
Table 16: Empliciti early-phase trial data in multiple myeloma
Table 17: Empliciti ongoing late-phase clinical trials in multiple myeloma
Table 18: Empliciti sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 19: Patients treated with Empliciti across the US, Japan, and five major EU markets, by country, 2017–26
Table 20: Farydak drug profile
Table 21: Farydak pivotal trial data in multiple myeloma
Table 22: Farydak early-phase trial data in multiple myeloma
Table 23: Farydak Phase II trial in multiple myeloma
Table 24: Farydak sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 25: Patients treated with Farydak across the US, Japan, and five major EU markets, by country, 2017–26
Table 26: Kyprolis drug profile
Table 27: Kyprolis pivotal trial data in multiple myeloma
Table 28: Kyprolis late-phase trial data in multiple myeloma
Table 29: Kyprolis early-phase trial data in multiple myeloma
Table 30: Kyprolis ongoing Phase III trials in multiple myeloma
Table 31: Kyprolis sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 32: Patients treated with Kyprolis across the US, Japan, and five major EU markets, by country, 2017–26
Table 33: Ninlaro drug profile
Table 34: Ninlaro pivotal trial data in multiple myeloma
Table 35: Ninlaro ongoing late-phase clinical trials in multiple myeloma
Table 36: Ninlaro sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 37: Patients treated with Ninlaro across the US, Japan, and five major EU markets, by country, 2017–26
Table 38: Pomalyst drug profile
Table 39: Pomalyst pivotal trial data in multiple myeloma
Table 40: Pomalyst late-phase trial data in multiple myeloma
Table 41: Pomalyst key ongoing clinical trials in multiple myeloma
Table 42: Pomalyst sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 43: Patients treated with Pomalyst across the US, Japan, and five major EU markets, by country, 2017–26
Table 44: Revlimid drug profile
Table 45: Revlimid pivotal trial data in multiple myeloma
Table 46: Revlimid ongoing clinical trials in multiple myeloma
Table 47: Revlimid sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 48: Patients treated with Revlimid across the US, Japan, and five major EU markets, by country, 2017–26
Table 49: Thalomid drug profile
Table 50: Thalomid pivotal trial data in multiple myeloma
Table 51: Thalomid late-phase trial data in multiple myeloma
Table 52: Thalomid sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 53: Patients treated with Thalomid across the US, Japan, and five major EU markets, by country, 2017–26
Table 54: Treanda/Bendeka drug profile
Table 55: Treanda early-phase trial data in multiple myeloma
Table 56: Patients receiving Treanda or generic bendamustine in the five major EU markets (%), by country
Table 57: Treanda/Bendeka sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 58: Patients treated with Treanda/Bendeka across the US, Japan, and five major EU markets, by country, 2017–26
Table 59: Velcade drug profile
Table 60: Velcade pivotal trial data in multiple myeloma
Table 61: Velcade late-phase trial data in multiple myeloma
Table 62: Velcade sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 63: Patients treated with Velcade in the US, Japan, and five major EU markets, by country, 2017–26
Table 64: Venclexta drug profile
Table 65: Venclexta Phase III trial in multiple myeloma
Table 66: Venclexta early-phase data in multiple myeloma
Table 67: Venclexta early-phase trials in multiple myeloma
Table 68: Venclexta sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 69: Patients treated with Venclexta in the US, Japan, and five major EU markets, by country, 2017–26
Table 70: Ygalo drug profile
Table 71: Ygalo Phase III trial in multiple myeloma
Table 72: Ygalo early-phase data in multiple myeloma
Table 73: Ygalo sales for multiple myeloma across the US and five major EU markets, by country ($m), 2017–26
Table 74: Patients treated with Ygalo in the US and five major EU markets, by country, 2017–26
Table 75: bb2121 drug profile
Table 76: bb2121 Phase II trial in multiple myeloma
Table 77: bb2121 early-phase data in multiple myeloma
Table 78: bb2121 sales for multiple myeloma across the US and five major EU markets, by country ($m), 2017–26
Table 79: Patients treated with bb2121 across the US and five major EU markets, by country, 2017–26
Table 80: isatuximab drug profile
Table 81: isatuximab Phase III trial in multiple myeloma
Table 82: Isatuximab Phase I/II data in multiple myeloma
Table 83: Isatuximab sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 84: Patients treated with isatuximab across the US, Japan, and five major EU markets, by country, 2017–26
Table 85: Selinexor drug profile
Table 86: Selinexor Phase III trial in multiple myeloma
Table 87: Selinexor early-phase data in multiple myeloma
Table 88: Selinexor sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 89: Patients treated with selinexor across the US, Japan, and five major EU markets, by country, 2017–26
Table 90: Medical oncologists and hematologists surveyed for the multiple myeloma primary research study, 2017
Table 91: Molecular subtypes of multiple myeloma
Table 92: Disease classification of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma
Table 93: Common symptoms of multiple myeloma
Table 94: Co-morbidities associated with multiple myeloma
Table 95: International Staging System for multiple myeloma
Table 96: Durie-Salmon staging system for multiple myeloma
Table 97: The revised International Staging System criteria for multiple myeloma
Table 98: Leading treatments available for multiple myeloma across the US, Japan, and five major EU markets
Table 99: Time to progression from smoldering multiple myeloma to active multiple myeloma, by country
Table 100: Durie-Salmon, International Staging System (ISS), and revised ISS (R-ISS) staging classifications for multiplemyeloma
Table 101: Cancer registry databases used as a source of multiple myeloma incidence data, by country
Table 102: Forecasting methodology for multiple myeloma incidence, by country, age group, and gender
Table 103: Frequency of ultra high-risk characteristics among smoldering multiple myeloma patients
Table 104: Data sources for the Revised International Staging System distribution of multiple myeloma
Table 105: Data sources for immunoglobulin isotype distribution of multiple myeloma, by country
Table 106: Sources of survival data used to estimate multiple myeloma prevalence, by country
Table 107: Validation of forecast estimates against benchmark estimates
Table 108: Diagnosed incident cases of multiple myeloma in the US, Japan, and five major EU markets, by country, 2017–37
Table 109: Profiled key marketed drugs for multiple myeloma
Table 110: Darzalex drug profile
Table 111: Darzalex pivotal trial data in multiple myeloma
Table 112: Darzalex early-phase trial data in multiple myeloma
Table 113: Darzalex Phase III trials in multiple myeloma
Table 114: Darzalex sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 115: Patients treated with Darzalex across the US, Japan, and five major EU markets, by country, 2017–26
Table 116: Empliciti drug profile
Table 117: Empliciti pivotal trial data in multiple myeloma
Table 118: Empliciti early-phase trial data in multiple myeloma
Table 119: Empliciti ongoing late-phase clinical trials in multiple myeloma
Table 120: Empliciti sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 121: Patients treated with Empliciti across the US, Japan, and five major EU markets, by country, 2017–26
Table 122: Farydak drug profile
Table 123: Farydak pivotal trial data in multiple myeloma
Table 124: Farydak early-phase trial data in multiple myeloma
Table 125: Farydak Phase II trial in multiple myeloma
Table 126: Farydak sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 127: Patients treated with Farydak across the US, Japan, and five major EU markets, by country, 2017–26
Table 128: Kyprolis drug profile
Table 129: Kyprolis pivotal trial data in multiple myeloma
Table 130: Kyprolis late-phase trial data in multiple myeloma
Table 131: Kyprolis early-phase trial data in multiple myeloma
Table 132: Kyprolis ongoing Phase III trials in multiple myeloma
Table 133: Kyprolis sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 134: Patients treated with Kyprolis across the US, Japan, and five major EU markets, by country, 2017–26
Table 135: Ninlaro drug profile
Table 136: Ninlaro pivotal trial data in multiple myeloma
Table 137: Ninlaro ongoing late-phase clinical trials in multiple myeloma
Table 138: Ninlaro sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 139: Patients treated with Ninlaro across the US, Japan, and five major EU markets, by country, 2017–26
Table 140: Pomalyst drug profile
Table 141: Pomalyst pivotal trial data in multiple myeloma
Table 142: Pomalyst late-phase trial data in multiple myeloma
Table 143: Pomalyst key ongoing clinical trials in multiple myeloma
Table 144: Pomalyst sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 145: Patients treated with Pomalyst across the US, Japan, and five major EU markets, by country, 2017–26
Table 146: Revlimid drug profile
Table 147: Revlimid pivotal trial data in multiple myeloma
Table 148: Revlimid ongoing clinical trials in multiple myeloma
Table 149: Revlimid sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 150: Patients treated with Revlimid across the US, Japan, and five major EU markets, by country, 2017–26
Table 151: Thalomid drug profile
Table 152: Thalomid pivotal trial data in multiple myeloma
Table 153: Thalomid late-phase trial data in multiple myeloma
Table 154: Thalomid sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 155: Patients treated with Thalomid across the US, Japan, and five major EU markets, by country, 2017–26
Table 156: Treanda/Bendeka drug profile
Table 157: Treanda early-phase trial data in multiple myeloma
Table 158: Patients receiving Treanda or generic bendamustine in the five major EU markets (%), by country
Table 159: Treanda/Bendeka sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 160: Patients treated with Treanda/Bendeka across the US, Japan, and five major EU markets, by country, 2017–26 572 Table 161: Velcade drug profile
Table 162: Velcade pivotal trial data in multiple myeloma
Table 163: Velcade late-phase trial data in multiple myeloma
Table 164: Velcade sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 165: Patients treated with Velcade in the US, Japan, and five major EU markets, by country, 2017–26
Table 166: Marketed multiple myeloma products and approved indications in the US, Japan, and five major EU markets
Table 167: Access levers for multiple myeloma treatments in the US and five major EU markets
Table 168: Pricing, market access, and reimbursement strategies for combination therapies
Table 169: Use of treatment algorithms and pathways to streamline prescribing within multiple myeloma across the US and five major EU markets
Table 170: Payer views on route of administration of multiple myeloma therapies
Table 171: Importance of multiple myeloma clinical trial endpoints in the US and five major EU markets
Table 172: Likely reimbursement of Darzalex in the front-line setting for transplant-ineligible multiple myeloma patients in the US and five major EU markets
Table 173: Reimbursement of Empliciti plus Rd in the second-line setting across the five major EU markets
Table 174: Reimbursement of Ninlaro plus Rd in the second-line setting across the five major EU markets
Table 175: Reimb
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll